My Application Form Status

Check the status of your application form with Angel Broking.
  • Companies
  • Everything else
Search
Future Enterprises standalone net profit rises 615.37% in the June 2016 quarter

Future Enterprises standalone net profit rises 615.37% in the June 2016 quarter

Sep 14,2016

Net profit of Future Enterprises rose 615.37% to Rs 315.48 crore in the quarter ended June 2016 as against Rs 44.10 crore during the previous quarter ended June 2015. Sales declined 67.64% to Rs 921.19 crore in the quarter ended June 2016 as against Rs 2846.84 crore during the previous quarter ended June 2015.

ParticularsQuarter Ended
n++Jun. 2016Jun. 2015% Var.
Sales921.192846.84-68
OPM %24.969.91-
PBDT295.07184.1360
PBT142.3249.92185
NP315.4844.10615

Powered by Capital Market - Live News

FICCI welcomes Department of Pharmaceuticals move towards broadbased stakeholder consultations
Aug 25,2016

The Department of Pharmaceuticals has involved hospitals and eminent clinicians, both from the Government and Private sectors in the important discussion on price control of coronary stents.

In this discussion on the subject of coronary stents inclusion in NLEM (National List of Essential Medicine), several reputed clinicians emphasized on the fact that all Drug Eluting Stents (DES) cannot be considered the same. There is sufficient clinical evidence that generational improvements in DES through incremental innovation has resulted in improved patient outcomes in the form of reduced rate of thrombosis and restenosis reduction for instance, in addition to ease of deliverability thus improving overall safety and efficacy. The suggestion that all DES is similar puts Indian patients and medical care in significant quality disadvantage.

The reputed clinicians experts present in the meeting have recommended to the Government to consider a DES classification norm through a matrix that involves such key performance parameters as:

a. Type of drug

b. Type of alloy

c. Strut thickness

d. Polymer profile

e. Deliverability / Trackability

f. Published safety & efficacy outcome data in publications of minimum impact factor of 2

g. Global regulatory approvals

There was consensus amongst Clinicians, Government and Industry that an appropriate Scoring Matrix, with critical patient safety and efficacy parameters, should be designed to determine DES classification. Industry has requested the Government to follow up through a multi stakeholder determination workshop, involving reputed clinicians, to design the matrix before Government activates the pricing mechanism for stents in NLEM.

FICCI, which has always maintained that all DES cannot be considered same and submitted extensive evidence of that to the NLEM Expert Committee in the past, welcomes the Department of Pharmaceuticals latest move towards a science, safety and efficacy based DES price determination process.

Powered by Capital Market - Live News

Trident wins awards for Excellence in Energy Management
Aug 25,2016

Trident announced that the Company has received following awards in 17th National Award for Excellence in Energy Management, an event organized by CII in Hyderabad:

1. Excellent Energy Efficient Unit - Paper & Chemical Division, Barnala

2. Energy Efficient Unit - Yarn Division, Budhni

These accolades add heaps of motivation and drive in Companys efforts to continue its product innovation, quality excellence and commitment.

Powered by Capital Market - Live News

Natco Pharma gains after marketing partner wins patent case
Aug 25,2016

The announcement was made during market hours today, 5 August 2016.

Meanwhile, the BSE Sensex was down 147.68 points, or 0.5%, to 27,920.22.

High volumes were witnessed on the counter. On BSE, so far 1.91 lakh shares were traded in the counter, compared with average daily volume of 70,932 shares in the past one quarter. The stock hit high of Rs 703.95, which is a record high for the stock. The stock hit a low of Rs 661.40 so far during the day. The stock hit a 52-week low of Rs 390 on 29 March 2016. The stock had outperformed the market over the past one month till 24 August 2016, gaining 9.93% compared with 0.92% rise in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 46.46% as against Sensexs 10.88% rise.

The large-cap company has equity capital of Rs 34.83 crore. Face value per share is Rs 2.

Natco Pharma announced that the US Patent and Trademark Office (PTO) has ruled in favour of its marketing partner, Mylan NV, in its inter partes review (IPR) proceeding against Teva Pharmaceutical Industries and found all claims of two related Copaxone 40 mg/mL patents to be unpatentable. The two US patents were owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceutical Industries Ltd. A decision by the PTAB on Mylans third petition seeking inter partes review of another patent is expected on or before 1 September 2016.

On 15 August 2016, the PTOs Patent Trial and Appeal Board (PTAB) found Mylans application against a fourth Copaxone 40 mg/mL patent, ineligible for post-grant review for procedural reasons. However, Mylan believes that todays favourable ruling in the IPR against these two patents strongly undermines that patent as well. As such, Mylan will proceed with pursuing all avenues to challenge that patent.

Natcos marketing partner, Mylan has filed a substantially complete abbreviated new drug application containing a Paragraph IV certification for a three times per week Glatiramer Acetate Injection 40 mg/mL, and expects to be eligible for 180 days of marketing exclusivity in the US upon final FDA approval. Copaxone 40 mg/mL had US sales of approximately $3.3 billion for the 12 months ending 30 June 2016, according to IMS Health.

Separately, Natco Pharma announced during market hours today, 5 August 2016, receipt of successful Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for the inspection conducted, during the period 8 February to 12 February 2016, at its chemical division in Chennai.

Natco Pharmas consolidated net profit rose 69.8% to Rs 47.65 crore on 38% rise in net sales to Rs 297.71 crore in Q1 June 2016 over Q1 June 2015.

Natco Pharma manufactures generic dosage forms, bulk actives and intermediates for the Indian and international markets.

Powered by Capital Market - Live News

Monsanto drops on reports of parent firm shelving plan to launch GM cotton
Aug 25,2016

Meanwhile, the S&P BSE Sensex was down 154.71 points, or 0.51%, to 27,916.38

On BSE, so far 6,925 shares were traded in the counter, compared with an average daily volume of 17,909 shares in the past one quarter. The stock hit a high of Rs 2,454.90 and a low of Rs 2,372.05 so far during the day. The stock had hit 52-week high of Rs 2,772 on 25 August 2015. The stock hit 52-week low of Rs 1,520 on 11 April 2016. The stock had outperformed the market over the past 30 days till 24 August 2016, rising 1.55% compared with Sensexs 0.3% rise. The scrip also outperformed the market in past one quarter, gaining 11.37% as against Sensexs 6.42% rise.

The mid-cap company has equity capital of Rs 17.26 crore. Face value per share is Rs 10.

As per reports, Monsanto Indias parent firm Monsanto Company, USA strongly objected to a government proposal that would force the company to share its technology with local seed companies. The company is also at loggerheads with government over how much it can charge for its genetically modified cotton seeds, costing it tens of millions of dollars in lost revenue every year, reports indicated.

Monsanto Indias net profit fell 9.86% to Rs 56.60 crore on 9.14% decline in net sales to Rs 236.08 crore in Q1 June 2016 over Q1 June 2015.

Monsanto India, a subsidiary of the Monsanto Company, USA is a seed company focusing on maize and agricultural productivity. Monsanto Company, USA, currently holds 72.14% stake in Monsanto India (as per the shareholding pattern as on 30 June 2016).

Powered by Capital Market - Live News

Infinite Computer Solutions India consolidated net profit rises 17.29% in the June 2016 quarter
Aug 25,2016

Net profit of Infinite Computer Solutions India rose 17.29% to Rs 29.91 crore in the quarter ended June 2016 as against Rs 25.50 crore during the previous quarter ended June 2015. Sales rose 13.84% to Rs 534.55 crore in the quarter ended June 2016 as against Rs 469.55 crore during the previous quarter ended June 2015.

ParticularsQuarter Endedn++Jun. 2016Jun. 2015% Var. Sales534.55469.55 14 OPM %8.718.15 - PBDT51.5242.26 22 PBT41.9430.55 37 NP29.9125.50 17

Powered by Capital Market - Live News

Cromakem reports standalone nil net profit/loss in the June 2016 quarter
Aug 25,2016

Cromakem reported no net profit/loss in the quarter ended June 2016 as against net profit of Rs 0.01 crore during the previous quarter ended June 2015. Sales declined 25.00% to Rs 0.18 crore in the quarter ended June 2016 as against Rs 0.24 crore during the previous quarter ended June 2015.

ParticularsQuarter Endedn++Jun. 2016Jun. 2015% Var. Sales0.180.24 -25 OPM %04.17 - PBDT00.01 -100 PBT00.01 -100 NP00.01 -100

Powered by Capital Market - Live News

Infinite Computer Solutions India standalone net profit rises 20.98% in the June 2016 quarter
Aug 25,2016

Net profit of Infinite Computer Solutions India rose 20.98% to Rs 23.24 crore in the quarter ended June 2016 as against Rs 19.21 crore during the previous quarter ended June 2015. Sales rose 6.19% to Rs 90.53 crore in the quarter ended June 2016 as against Rs 85.25 crore during the previous quarter ended June 2015.

ParticularsQuarter Endedn++Jun. 2016Jun. 2015% Var. Sales90.5385.25 6 OPM %34.1923.55 - PBDT34.3724.14 42 PBT30.9320.60 50 NP23.2419.21 21

Powered by Capital Market - Live News

Praveen Properties reports standalone nil net profit/loss in the June 2016 quarter
Aug 25,2016

Praveen Properties reported no net profit/loss in the quarter ended June 2016 and during the previous quarter ended June 2015. There were no Sales reported in the quarter ended June 2016 and during the previous quarter ended June 2015.

Powered by Capital Market - Live News

Citizen Yarns standalone net profit rises 50.00% in the June 2016 quarter
Aug 25,2016

Net profit of Citizen Yarns rose 50.00% to Rs 0.03 crore in the quarter ended June 2016 as against Rs 0.02 crore during the previous quarter ended June 2015. Sales rose 3.21% to Rs 4.83 crore in the quarter ended June 2016 as against Rs 4.68 crore during the previous quarter ended June 2015.

ParticularsQuarter Endedn++Jun. 2016Jun. 2015% Var. Sales4.834.68 3 OPM %0.620.43 - PBDT0.030.02 50 PBT0.030.02 50 NP0.030.02 50

Powered by Capital Market - Live News

Noble Polymers reports standalone net profit of Rs 0.03 crore in the June 2016 quarter
Aug 25,2016

Net profit of Noble Polymers reported to Rs 0.03 crore in the quarter ended June 2016. There were no net profit/loss reported during the previous quarter ended June 2015. Sales rose 975.00% to Rs 3.01 crore in the quarter ended June 2016 as against Rs 0.28 crore during the previous quarter ended June 2015.

ParticularsQuarter Endedn++Jun. 2016Jun. 2015% Var. Sales3.010.28 975 OPM %1.000 - PBDT0.030 0 PBT0.030 0 NP0.030 0

Powered by Capital Market - Live News

S P Apparels consolidated net profit rises 143.77% in the June 2016 quarter
Aug 25,2016

Net profit of S P Apparels rose 143.77% to Rs 16.43 crore in the quarter ended June 2016 as against Rs 6.74 crore during the previous quarter ended June 2015. Sales rose 32.88% to Rs 149.78 crore in the quarter ended June 2016 as against Rs 112.72 crore during the previous quarter ended June 2015.

ParticularsQuarter Endedn++Jun. 2016Jun. 2015% Var. Sales149.78112.72 33 OPM %21.5116.01 - PBDT27.5115.02 83 PBT22.6410.12 124 NP16.436.74 144

Powered by Capital Market - Live News

Man Infraconstruction consolidated net profit rises 104.30% in the June 2016 quarter
Aug 25,2016

Net profit of Man Infraconstruction rose 104.30% to Rs 12.36 crore in the quarter ended June 2016 as against Rs 6.05 crore during the previous quarter ended June 2015. Sales declined 6.58% to Rs 39.05 crore in the quarter ended June 2016 as against Rs 41.80 crore during the previous quarter ended June 2015.

ParticularsQuarter Endedn++Jun. 2016Jun. 2015% Var. Sales39.0541.80 -7 OPM %26.5811.89 - PBDT15.4813.43 15 PBT14.0711.50 22 NP12.366.05 104

Powered by Capital Market - Live News

Nava Bharat Ventures consolidated net profit declines 32.05% in the June 2016 quarter
Aug 25,2016

Net profit of Nava Bharat Ventures declined 32.05% to Rs 29.21 crore in the quarter ended June 2016 as against Rs 42.99 crore during the previous quarter ended June 2015. Sales declined 9.32% to Rs 313.72 crore in the quarter ended June 2016 as against Rs 345.96 crore during the previous quarter ended June 2015.

ParticularsQuarter Endedn++Jun. 2016Jun. 2015% Var. Sales313.72345.96 -9 OPM %21.6919.13 - PBDT75.4166.13 14 PBT52.9945.94 15 NP29.2142.99 -32

Powered by Capital Market - Live News

Vardhman Textiles consolidated net profit rises 24.16% in the June 2016 quarter
Aug 25,2016

Net profit of Vardhman Textiles rose 24.16% to Rs 178.27 crore in the quarter ended June 2016 as against Rs 143.58 crore during the previous quarter ended June 2015. Sales rose 0.97% to Rs 1474.17 crore in the quarter ended June 2016 as against Rs 1460.00 crore during the previous quarter ended June 2015.

ParticularsQuarter Endedn++Jun. 2016Jun. 2015% Var. Sales1474.171460.00 1 OPM %23.5121.21 - PBDT320.82285.28 12 PBT237.70195.82 21 NP178.27143.58 24

Powered by Capital Market - Live News

S P Apparels standalone net profit rises 86.90% in the June 2016 quarter
Aug 25,2016

Net profit of S P Apparels rose 86.90% to Rs 13.27 crore in the quarter ended June 2016 as against Rs 7.10 crore during the previous quarter ended June 2015. Sales rose 27.27% to Rs 149.08 crore in the quarter ended June 2016 as against Rs 117.14 crore during the previous quarter ended June 2015.

ParticularsQuarter Endedn++Jun. 2016Jun. 2015% Var. Sales149.08117.14 27 OPM %20.4315.71 - PBDT25.6715.38 67 PBT20.3510.53 93 NP13.277.10 87

Powered by Capital Market - Live News